Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RZL-012 for Fat Reduction in Flanks
NCT05445557Phase 2Completed
- Sponsor
- Raziel Therapeutics
- Start
- Mar 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Tapencarium in localized adiposity (AL), sponsored by Raziel Therapeutics. Started Mar 2022; status: completed.
02
Drugs
Tapencarium
03
Conditions
localized adiposity (AL)
Beyond the preview
Go deeper on NCT05445557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05445557.